

US00D605229S

(12) **United States Design Patent**  
**Langan et al.**

(10) **Patent No.:** **US D605,229 S**  
(45) **Date of Patent:** **\*\* Dec. 1, 2009**

(54) **DRUG ADMINISTRATION SAFETY LABEL**

4,065,343 A 12/1977 Stumpe  
4,815,768 A 3/1989 Applebaum et al.  
D311,423 S 10/1990 DeSantis

(75) Inventors: **Amy E. Langan**, Glenview, IL (US);  
**Richard J. Kruzynski**, Long Grove, IL (US);  
**John A. Kollar**, Northbrook, IL (US);  
**Patricia L. Miyake**, Mundelein, IL (US);  
**Monique L. Kruk**, Burlington, WI (US);  
**Mark F. Wagner**, Gurnee, IL (US)

(Continued)

**OTHER PUBLICATIONS**

(73) Assignee: **PharMEDium Services, LLC**, Lake Forest, IL (US)

Syringe label for Atropine sulfate, known prior to Dec. 3, 2007, 1 page.

Label for alcohol preps, known prior to Dec. 3, 2007, 1 page.

IV bag label for 0.9% Sodium Chloride, known prior to Dec. 3, 2007, 1 page.

Syringe label for Labetalol Hydrochloride, known prior to Dec. 3, 2007, 1 page.

Label for drug vial for 0.9% Sodium Chloride, known prior to Dec. 3, 2007, 1 page.

(\*\*) Term: **14 Years**

(21) Appl. No.: **29/343,298**

(22) Filed: **Sep. 10, 2009**

(Continued)

**Related U.S. Application Data**

(62) Division of application No. 29/332,179, filed on Feb. 10, 2009, which is a division of application No. 29/298,328, filed on Dec. 3, 2007, now Pat. No. Des. 588,200.

*Primary Examiner*—Janice E Seeger

*Assistant Examiner*—Mary Ann Calabrese

(74) *Attorney, Agent, or Firm*—K&L Gates LLP

(51) **LOC (9) Cl.** ..... **19-08**

(52) **U.S. Cl.** ..... **D20/27**

(58) **Field of Classification Search** ..... D20/10,  
D20/11, 13, 22–27, 99; 40/124.01, 124.02,  
40/124.04, 299.01, 310, 325, 360, 326, 538,  
40/541, 584, 594, 600, 630, 638; D19/1,  
D19/9, 10; 206/63.3, 534; 235/50 A; 283/51,  
283/56, 67, 71, 74, 75, 81, 99–101, 107–109,  
283/114, 117; 359/2; 428/40.1, 40.2, 42.1–42.3,  
428/914

See application file for complete search history.

(57) **CLAIM**

The ornamental design for a drug administration safety label, as shown and described.

**DESCRIPTION**

FIG. 1 is a top plan view of one embodiment of a drug administration safety label of our new design; and,

FIG. 2 is a top plan view of an alternative embodiment of a drug administration safety label of our new design.


In the drawings, the broken lines represent environmental structure forming no part of the claimed design.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

3,722,793 A \* 3/1973 Aronoff ..... 235/50 A

**1 Claim, 2 Drawing Sheets**



# US D605,229 S

Page 2

---

## U.S. PATENT DOCUMENTS

5,426,520 A 6/1995 Kakae et al.  
D386,212 S 11/1997 Lambert  
5,924,561 A 7/1999 Baumgartner et al.  
6,089,611 A 7/2000 Blank  
D432,176 S 10/2000 Stevens et al.  
6,299,213 B1 10/2001 Souparis  
D453,529 S 2/2002 Roth  
D412,131 S 5/2003 Takahashi et al.  
D500,524 S 1/2005 Stewart et al.  
D522,065 S 5/2006 Greenstein  
D550,287 S 9/2007 Smart et al.  
7,311,205 B2 12/2007 Adler et al.  
D584,361 S \* 1/2009 Davies ..... D20/27  
D588,200 S 3/2009 Langan et al.

D593,613 S \* 6/2009 Langan et al. .... D20/27  
D597,608 S \* 8/2009 Langan et al. .... D20/27  
2007/0029788 A1 2/2007 Adler  
2007/0252378 A1 11/2007 Chambers

## OTHER PUBLICATIONS

Syringe label for Calcium Chloride, known prior to Dec. 3, 2007, 1 page.  
Drug delivery device label for Phenylephrine, known prior to Dec. 3, 2007, 1 page.  
Label for drug vial for Phenylephrine, known prior to Dec. 3, 2007, 1 page.  
IV bag label for Fentanyl and Ropivacaine, known prior to Dec. 3, 2007, 1 page.

\* cited by examiner

FIG. 1




FIG. 2

